SCHEMBL1422926

SCHEMBL1422926

Cc1cc(C)n2ncc(C(=O)O)c2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 1.00
ALDH1A1 P00352 9/20 0.61
HPGD P15428 5/20 0.61
POLB P06746 2/20 0.59
MAPT P10636 3/20 0.56
GBA1 P04062 2/20 0.56
CYP1A1 P04798 1/20 0.55
GAA P10253 2/20 0.54
HSD17B10 Q99714 3/20 0.53
USP2 O75604 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
PLEC Q15149 1/20 0.52
PKM P14618 1/20 0.51
HTR6 P50406 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
HSD11B1 P28845 1/20 0.50
PDE2A O00408 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21238857 0.88 KDM4E (0.79) KDM4EALDH1A1HPGDPOLBMAPT
SCHEMBL2930949 0.87 KDM4E (0.77) KDM4EALDH1A1HPGDPOLBMAPT
SCHEMBL17739788 0.87 KDM4E (0.77) KDM4EALDH1A1HPGDPOLBMAPT
SCHEMBL18208953 0.85 KDM4E (0.73) KDM4EALDH1A1HPGDPOLBMAPT
SCHEMBL9926694 0.84 KDM4E (0.72) KDM4EALDH1A1HPGDPOLBMAPT
SCHEMBL13778001 0.84 KDM4E (0.72) KDM4EALDH1A1HPGDPOLBMAPT
SCHEMBL10407365 0.83 KDM4E (0.71) KDM4EALDH1A1HPGDPOLBMAPT
SCHEMBL9300782 0.83 KDM4E (0.71) KDM4EALDH1A1HPGDPOLBMAPT
SCHEMBL17732308 0.83 KDM4E (0.71) KDM4EALDH1A1HPGDPOLBMAPT
SCHEMBL17732306 0.83 KDM4E (0.71) KDM4EALDH1A1HPGDPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP claimed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP claimed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO claimed
US-20250340558-A1 CRYSTALLINE SUBSTITUTED CYCLOHEXYL PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUND AND THERAPEUTIC USES THEREOF BIAL R&D INVEST S A (PT) 2025-11-06 US disclosed
WO-2025198486-A1 PROCESS FOR PREPARING A PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUND BIAL – R&D Investments, S.A. (PT) 2025-09-25 WO disclosed
US-20250066364-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2025-02-27 US disclosed
US-12116369-B2 Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators Bial—R&D Investments, S.A. (PT) 2024-10-15 US disclosed
EP-4406616-A2 SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Bial-R&D Investments, S.A. (PT) 2024-07-31 EP disclosed
EP-3215511-B1 SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2024-04-17 EP disclosed
US-11932645-B2 Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders Bial—R & D Investments, S.A. (PT) 2024-03-19 US disclosed
CN-115925711-A Substituted pyrazolo [1,5-a ] pyrimidines and their use in treating medical disorders BIAL研发投资股份有限公司 2023-04-07 CN disclosed
US-7491821-B2 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders ROCHE PALO ALTO LLC (US) 2009-02-17 US disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO disclosed
EP-1956009-A1 AROMATIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2008-08-13 EP disclosed
EP-1917262-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2008-05-07 EP disclosed
WO-2007020194-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-02-22 WO disclosed
US-20070037974-A1 Inhibitors of P2X3 ROCHE PALO ALTO LLC 2007-02-15 US disclosed
US-4908056-A Herbicides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1990-03-13 US disclosed
US-4838925-A HERBICIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-06-13 US disclosed
EP-0244166-A2 Heterocyclic acetyl sulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12116369-B2 Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators GBA1, GALC, GBA3 KDM4E 1067/4885ALDH1A1 1260/4885HPGD 2491/4885
US-20070037974-A1 Inhibitors of P2X3 P2RX3, P2RX4, P2RX5 KDM4E 1047/4885ALDH1A1 2159/4885HPGD 4003/4885
US-11932645-B2 Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders PARK7, PNP, GAA KDM4E 899/4885ALDH1A1 1213/4885HPGD 1396/4885
US-20250340558-A1 CRYSTALLINE SUBSTITUTED CYCLOHEXYL PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUND AND THERAPEUTIC USES THEREOF GBA1, GAA, PARK7 KDM4E 1033/4885ALDH1A1 3776/4885HPGD 2660/4885
US-20250066364-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS PARK7, PNP, GAA KDM4E 899/4885ALDH1A1 1213/4885HPGD 1396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.